These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 23240787)
41. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. Roujeau JC; Kelly JP; Naldi L; Rzany B; Stern RS; Anderson T; Auquier A; Bastuji-Garin S; Correia O; Locati F N Engl J Med; 1995 Dec; 333(24):1600-7. PubMed ID: 7477195 [TBL] [Abstract][Full Text] [Related]
42. The use of dabigatran immediately after atrial fibrillation ablation. Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA J Cardiovasc Electrophysiol; 2012 Mar; 23(3):264-8. PubMed ID: 21955008 [TBL] [Abstract][Full Text] [Related]
43. Ciprofloxacin-induced toxic epidermal necrolysis. Moshfeghi M; Mandler HD Ann Pharmacother; 1993 Dec; 27(12):1467-9. PubMed ID: 8305780 [TBL] [Abstract][Full Text] [Related]
45. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181 [TBL] [Abstract][Full Text] [Related]
46. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Hohnloser SH; Oldgren J; Yang S; Wallentin L; Ezekowitz M; Reilly P; Eikelboom J; Brueckmann M; Yusuf S; Connolly SJ Circulation; 2012 Feb; 125(5):669-76. PubMed ID: 22215856 [TBL] [Abstract][Full Text] [Related]
47. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with paediatric patients in a university hospital. Ferrándiz-Pulido C; García-Fernández D; Domínguez-Sampedro P; García-Patos V J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1153-9. PubMed ID: 21198948 [TBL] [Abstract][Full Text] [Related]
48. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Bytzer P; Connolly SJ; Yang S; Ezekowitz M; Formella S; Reilly PA; Aisenberg J Clin Gastroenterol Hepatol; 2013 Mar; 11(3):246-52.e1-5. PubMed ID: 23103906 [TBL] [Abstract][Full Text] [Related]
49. [Bullous drug eruption with Nigella sativa oil]. Gelot P; Bara-Passot C; Gimenez-Arnau E; Beneton N; Maillard H; Celerier P Ann Dermatol Venereol; 2012 Apr; 139(4):287-91. PubMed ID: 22482483 [TBL] [Abstract][Full Text] [Related]
50. Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients. Prescrire Int; 2012 Feb; 21(124):33-6. PubMed ID: 22413715 [TBL] [Abstract][Full Text] [Related]
51. Dabigatran for stroke prevention in all patients with atrial fibrillation? Hunchuck JE; Lake JD Pharmacotherapy; 2011 Aug; 31(8):725-8. PubMed ID: 21923597 [No Abstract] [Full Text] [Related]
52. [Stevens-Johnson syndrome and toxic epidermal necrolysis in children]. Sotelo-Cruz N Gac Med Mex; 2012; 148(3):265-75. PubMed ID: 22820360 [TBL] [Abstract][Full Text] [Related]
53. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. Mockenhaupt M; Kelly JP; Kaufman D; Stern RS; J Rheumatol; 2003 Oct; 30(10):2234-40. PubMed ID: 14528522 [TBL] [Abstract][Full Text] [Related]
54. Hemorrhagic complications associated with dabigatran use. Chen BC; Viny AD; Garlich FM; Basciano P; Howland MA; Smith SW; Hoffman RS; Nelson LS Clin Toxicol (Phila); 2012 Nov; 50(9):854-7. PubMed ID: 22970730 [TBL] [Abstract][Full Text] [Related]
55. Toxic epidermal necrolysis/Stevens-Johnson syndrome: current trends in management. Dalli RL; Kumar R; Kennedy P; Maitz P; Lee S; Johnson R ANZ J Surg; 2007 Aug; 77(8):671-6. PubMed ID: 17635282 [TBL] [Abstract][Full Text] [Related]